Innovative Oncology Platforms Nammi Therapeutics specializes in immuno-oncology with advanced platforms that activate anti-tumor immunity locally within the tumor microenvironment, presenting opportunities to collaborate on targeted cancer therapies or complementary immune-modulating solutions.

Recent Funding Growth With a recent $1M investment from the Myeloma Investment Fund, Nammi is positioned to expand its clinical development efforts, highlighting potential areas for strategic partnerships or co-investment opportunities in innovative cancer treatment technologies.

Early-Stage Market Presence As a small, emerging company with revenue between $1M and $10M, Nammi offers opportunities for early engagement with innovative biotech solutions, making them a potential partner for organizations looking to expand into cutting-edge immunotherapy markets.

Targeted Immunotherapies Nammi’s lead candidate, QXL138AM, a masked immunocytokine targeting tumor-specific antigens, suggests potential sales opportunities in targeted biologics and immune modulator markets, especially for organizations focusing on precision oncology solutions.

Technology-Driven Innovation Their proprietary platforms, including MIC and Nammisome nanoparticle technology, open avenues for collaborations on next-generation delivery systems and immune activation strategies, appealing to biotech and pharmaceutical companies seeking innovative therapeutic platforms.